// App-Quantinova.ai

2970 : MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent in vitro and in vivo activity in preclinical studies

Researchers

Presenter

  • John Li

Principal Investigators

  • Dorin Toader

  • Samuel R. Perry

  • Vanessa Muniz-Medina

  • Leslie Wetzel

  • Marlon C. Rebelatto

  • Mary Jane Masson Hinrichs

  • Ryan Fleming

  • Binyam Bezabeh

  • Pamela Thompson

  • Nazzareno Dimasi

  • Brandon Lam

  • Xian-Qing Yu

  • Changshou Gao

  • Rakesh Dixit

  • Steven Coats

  • Jane Osbourn

  • Herren Wu

Medical Centers

  • MedImmune, Gaithersburg, MD

  • MedImmune, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • MedImmune Inc. (Astr

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

  • Apparent diffusion coefficient

Drug/Treatment

  • tubulysin

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved